2015
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 2015, 121: 2544-2552. PMID: 25902916, DOI: 10.1002/cncr.29348.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyNAC useBreast cancerStage INational Cancer Data BaseStage III breast cancerStage IIIC cancerStage II diseaseStage III diseaseAdvanced breast cancerStandard of careLow-stage cancersLogistic regression analysisChi-square testIIIC cancersStage IIIAStage IIIBAdvanced cancerAfrican American individualsStage cancerPatterns of usePatientsAcademic centersClinical advantagesMultivariate analysis
2004
Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma
Gonzalez‐Angulo A, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004, 101: 258-263. PMID: 15241821, DOI: 10.1002/cncr.20348.Peer-Reviewed Original ResearchConceptsEarly-stage breast carcinomaBreast carcinomaTumor specimensPathologic responseStage II breast carcinomaAJCC stage IIMedian patient ageStage III diseasePathologic complete responseOverall survival rateLack of associationGene amplificationPreoperative chemotherapyRecurrent diseaseComplete responsePatient agePatientsCarcinomaSurvival rateTissue specimensStage IITaxanesHormone receptorsTumorsDisease